Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-20-7495-2379
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable
Tiziana Life Sciences (NASDAQ:TLSA) Frequently Asked Questions
What is Tiziana Life Sciences' stock symbol?
Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA."
When is Tiziana Life Sciences' next earnings date?
What price target have analysts set for TLSA?
1 analysts have issued twelve-month price targets for Tiziana Life Sciences' stock. Their forecasts range from $20.00 to $20.00. On average, they expect Tiziana Life Sciences' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 635.3% from the stock's current price. View Analyst Price Targets for Tiziana Life Sciences.
What is the consensus analysts' recommendation for Tiziana Life Sciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tiziana Life Sciences.
Has Tiziana Life Sciences been receiving favorable news coverage?
Press coverage about TLSA stock has been trending somewhat negative this week, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tiziana Life Sciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Tiziana Life Sciences.
Who are some of Tiziana Life Sciences' key competitors?
Some companies that are related to Tiziana Life Sciences include Hookipa Pharma (HOOK), Wave Life Sciences (WVE), BIOFRONTERA AG/ADR (BFRA), Kala Pharmaceuticals (KALA), Neptune Wellness Solutions (NEPT), Sol Gel Technologies (SLGL), VBI Vaccines (VBIV), Avadel Pharmaceuticals (AVDL), Evofem Biosciences (EVFM), MEI Pharma (MEIP), Concert Pharmaceuticals (CNCE), Affimed (AFMD), Seres Therapeutics (MCRB), Theratechnologies (THERF) and Ocular Therapeutix (OCUL).
What other stocks do shareholders of Tiziana Life Sciences own?
Who are Tiziana Life Sciences' key executives?
Tiziana Life Sciences' management team includes the folowing people:
- Mr. Gabriele Marco Antonio Cerrone, Founder & Exec. Chairman (Age 46)
- Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 60)
- Dr. Andrea Brancale Ph.D., Scientific Founder
- Mr. Richard Clarkson Ph.D., Scientific Founder
- Mr. Andrew Westwell Ph.D., Scientific Founder
When did Tiziana Life Sciences IPO?
(TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.
How do I buy shares of Tiziana Life Sciences?
Shares of TLSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tiziana Life Sciences' stock price today?
One share of TLSA stock can currently be purchased for approximately $2.72.
How big of a company is Tiziana Life Sciences?
What is Tiziana Life Sciences' official website?
How can I contact Tiziana Life Sciences?
Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7495-2379 or via email at [email protected]
MarketBeat Community Rating for Tiziana Life Sciences (NASDAQ TLSA)
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences and other stocks. Vote "Outperform" if you believe TLSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
